Antipsychotic-evoked dopamine supersensitivity.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Antipsychotics manage psychosis by targeting dopamine D2 receptors.
• Chronic use may lead to dopamine supersensitivity, impacting treatment efficacy and causing side effects like movement disorders in schizophrenia patients.
• This phenomenon is observed in both typical and atypical antipsychotic users, as well as in animal models.

Purpose of the Study:

• To review antipsychotic-induced dopamine supersensitivity in schizophrenia patients and animal models.
• To explore strategies for preventing or reversing this neuroadaptation based on preclinical data.
• To discuss underlying neurobiological mechanisms and their implications for treatment.

Main Methods:

• Review of existing literature on dopamine supersensitivity.
• Analysis of preclinical animal studies on antipsychotic effects.
• Discussion of neurobiological mechanisms and clinical implications.

Main Results:

• Antipsychotic medications can induce dopamine supersensitivity, linked to reduced treatment effectiveness and adverse effects.
• Preclinical data suggest atypical antipsychotics and intermittent dosing schedules are less likely to cause dopamine supersensitivity compared to continuous treatment.
• Potential mechanisms involve changes at the D2 receptor and other dopamine system components.

Conclusions:

• Understanding dopamine supersensitivity is crucial for optimizing long-term antipsychotic therapy in schizophrenia.
• Further research is needed to characterize dopamine supersensitivity development in humans and identify optimal dosing strategies.
• Investigating different dosing regimens and receptor occupancy is essential for improving patient outcomes.